AI in Healthcare Pulse — 2026-11-17
Recent reporting points to two developments to track: a federal roadmap intended to support safe clinical AI deployment and an FDA terminology change that sources say does not alter medical-product requirements. Remedy Robotics also announced a $62 million Series B to develop cardiovascular-care robotics.
AI in Healthcare Pulse — 2026-11-17
Regulatory & Policy Watch
- What happened: The Trump administration released a roadmap intended to boost clinical AI, described as building on existing policies for safe deployment. Impact: The report signals a federal push to support clinical AI, though the available summary does not detail specific requirements or implementation steps.

- What happened: The FDA will use “super intelligence” rather than “artificial intelligence” in new documents and communications, while sponsors may continue using “AI.” A second report says the terminology change does not alter medical-product regulatory requirements. Impact: The change affects agency wording, not the regulatory requirements described in the report.

Funding & Deals
Remedy Robotics — $62 million Series B
- What they do: Remedy Robotics describes itself as a healthcare and physical AI company developing robotic systems for cardiovascular care.
- Why it matters: The round is a fresh financing signal for companies combining AI with robotic cardiovascular-care systems. The available report did not identify investors.
What to Watch Next Week
- Track whether the federal clinical AI roadmap is followed by more detailed guidance or implementation steps; the available report describes its aim but not its specifics.
- Watch for further FDA communications using the new terminology and whether agency materials clarify how it will be applied.
- Follow updates from Remedy Robotics on its newly announced cardiovascular-care robotics financing.
Reader Action Items
- Healthcare AI teams: review the federal roadmap directly before drawing conclusions about its operational implications; the available summary does not provide specific implementation details.
- Regulatory and compliance teams: distinguish the FDA’s reported terminology change from changes to product requirements; the cited coverage says the rebrand does not alter those requirements.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.